|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on April 30, 2002; DOI 10.1182/blood-2002-02-0350.
REVIEW ARTICLE
From the Department of Internal Medicine, Division of
Hematology/Oncology, and the Comprehensive Cancer Center, The Ohio
State University, Columbus; and The Division of Hematology and Clinical
Immunology, The Department of Clinical and Experimental Medicine,
University of Perugia, Perugia, Italy.
Natural killer (NK) cells have held great promise for the
immunotherapy of cancer for more than 3 decades. However, to date only
modest clinical success has been achieved manipulating the NK cell
compartment in patients with malignant disease. Progress in the field
of NK cell receptors has revolutionized our concept of how NK cells
selectively recognize and lyse tumor and virally infected cells while
sparing normal cells. Major families of cell surface receptors that
inhibit and activate NK cells to lyse target cells have been
characterized, including killer cell immunoglobulinlike receptors
(KIRs), C-type lectins, and natural cytotoxicity receptors (NCRs).
Further, identification of NK receptor ligands and their expression on
normal and transformed cells completes the information needed to begin
development of rational clinical approaches to manipulating
receptor/ligand interactions for clinical benefit. Indeed, clinical
data suggest that mismatch of NK receptors and ligands during
allogeneic bone marrow transplantation may be used to prevent leukemia
relapse. Here, we review how NK cell receptors control natural
cytotoxicity and novel approaches to manipulating NK receptor-ligand
interactions for the potential benefit of patients with cancer.
(Blood. 2002;100:1935-1947) Over the past 2 decades, a number of different
immune-based strategies aimed at eradication or suppression of residual
malignant disease have been proposed for the clearance of leukemic
cells. T-cell-mediated graft-versus-leukemia (GVL) has been
shown to be the most efficacious following allogeneic hematopoietic
stem cell transplantation and donor lymphocyte
infusions.1,2 Although specific antileukemic responses
have been documented, most T-cell-mediated alloreactions are thought
to be directed against minor or major histocompatibility antigens
shared by both leukemic and normal cells with potential for widespread
host tissue damage. Successful T-cell-based immunotherapy will,
therefore, ultimately require better definition of tumor-specific
antigens that will allow the direction of the immune response to the
tumor cells.3 Unfortunately, tumor-specific antigens have
only been identified on a minority of cancers.4
In contrast to antigen-specific T cells, effector cells of the innate
immune system lack the ability to rearrange the genes in the germ line
that encode receptor components, and, hence, they cannot recognize a
multitude of antigens in the context of classical major
histocompatibility complex (MHC) molecules. Natural killer (NK) cells
are innate immune lymphocytes that held early clinical promise because
of their ability to lyse tumor cells without specific antigen
recognition.5,6 Clinical trials attempting to harness the
antitumor effect of NK cells, either through in vivo or in vitro
activation, have met with only modest success to date.7-9
However, over the past decade our knowledge of how NK cells recognize
target cells using an integration of activating and inhibitory
receptors now points toward potential clinical utility for the
treatment of leukemia and other malignancies. In this review we
summarize our current understanding of the receptors involved in NK
cell recognition of tumor targets and discuss their potential clinical
role in immunotherapy of leukemia with and without hematopoietic stem
cell transplantation.
NK cells are innate immune lymphocytes critical to host defense
against invading infectious pathogens and malignant transformation through elaboration of cytokines and cytolytic
activity.5,6,10 Human NK cells comprise approximately 10%
of all blood lymphocytes and are identified by the expression of the
CD56 surface antigen and the lack of CD3. Functionally, NK cells are an
important source of innate immunoregulatory cytokines (eg,
interferon- Two distinct subsets of human NK cells are identified according to
cell surface density of CD56 expression as recently reviewed elsewhere.10 The majority (90%) of human NK cells are
CD56dim and express high levels of CD16, whereas a minority
(10%) is CD56bright and CD16dim/neg. These NK
subsets are functionally distinct with the immunoregulatory CD56bright cells producing abundant cytokines and the
cytotoxic CD56dim cells likely functioning as efficient
effectors of natural and antibody-dependent target cell
lysis.15 CD56bright NK cells constitutively
express the high and intermediate affinity interleukin (IL)-2 receptors
and expand in vitro and in vivo in response to low (picomolar) doses of
IL-2.8,16 In contrast, resting CD56dim NK
cells express only the intermediate-affinity IL-2 receptor and
proliferate weakly in response to high doses of IL-2 (1-10 nM) in
vitro, even after induction of the high-affinity IL-2
receptor.16,17 Resting CD56dim NK cells are
more cytotoxic against NK-sensitive targets (K562 and COLO205 cell
lines) than CD56bright NK cells.18 However,
after activation with IL-2 or IL-12, CD56bright cells
exhibit similar or enhanced cytotoxicity against NK targets compared
with CD56dim cells.18-20 In addition, resting
CD56bright and CD56dim NK cell subsets show
differences in their NK receptor repertoires.21,22 Resting
CD56bright NK cells are large agranular cells and express
high levels of the C-type lectin CD94/NKG2 family with only very small
fractions expressing killer-cell immunoglobulin receptor (KIR)
family.18 Resting CD56dim NK cells, however,
express both KIR and C-type lectin NK receptors at relatively high
surface density along with an abundance of cytolytic granules packaged
in the cytoplasm.18
NK cells originate in the bone marrow from human CD34+
hematopoietic progenitor cells (HPCs) and require the bone marrow
microenvironment for complete maturation. Bone marrow stroma-derived
cytokines, including IL-15 in cooperation with c-kit ligand (KL) and
flt-3 ligand (FL), are critical physiologic factors for NK cell
development, as recently reviewed.23 Human NK cell
development can be divided into an early phase of development in which
a NK progenitor responds to early acting stromal cell growth factors,
KL and FL, and develops into an NK cell precursor intermediate with the
phenotype
CD34+IL-2/ IL-15R Unlike T and B lymphocytes, NK cells do not rearrange genes
encoding receptors for antigen recognition, but they have developed the
ability to recognize self-MHC class I or class I-like molecules through a unique class of receptors, NK cell receptors (NKRs), that can
inhibit or activate NK cell killing. Initially, Ljunggren and
Karre27 proposed the "missing-self" hypothesis,
wherein the function of NK cells is to recognize and destroy autologous cells that have lost or altered self-MHC class I molecules. Although tolerant to normal autologous cells, NK cells can recognize and attack
virus-infected and transformed cells that have down-regulated MHC class
I molecules. Human NK cells lyse class I-deficient Epstein-Barr virus
(EBV)-transformed B-lymphoblastoid cell lines, whereas transfection of
class I alleles into target cells inhibits NK lysis.28,29 Accordingly, over the past decade, a number of inhibitory NK receptors specific for classical (eg, HLA-A, -B, or -C) or nonclassical (eg,
HLA-E, -G) class I molecules have been recognized.
However, MHC class I is not always necessary for protection from lysis
by NK cells, and inhibition by MHC class I is not always sufficient to
prevent NK cytotoxicity. For example, NK cells are unable to reject MHC
class I-deficient nonhematopoietic tissues, such as skin grafts, and
in vitro they fail to lyse fibroblasts, even from
KIRs belong to the immunoglobulin superfamily and are
characterized structurally by 2 or 3 extracellular immunoglobulinlike domains. KIRs specifically recognize MHC class I alleles, including groups of HLA-A,36,37 HLA-B,38-40 and
HLA-C.38,41,42 There are 2 functionally distinct sets of
KIRs: inhibitory and activating. Each set has an identical
extracellular domain, and, consequently, each set binds to identical
ligands. However, because of differences in their transmembrane and
intracellular or cytoplasmic domains, one set of KIRs signals an
inhibitory response and one set signals an activating response
following their binding to identical MHC class I alleles (Figure
2).43,44
The KIR family of NKR, located on chromosome 19p13.4,45,46
includes 12 members and a number of allelic variants, of which 6 receptors are inhibitory and 6 are activating. These are monomeric (single chain) receptors with either 2 (KIR2D) or 3 immunoglobulinlike domains (KIR3D), which can be further subdivided into those with long
(L) cytoplasmic tails (KIR2DL and KIR3DL) and short (S) cytoplasmic tails (KIR2DS and KIR3DS) (Figure 2). The long tail KIRs generate an
inhibitory signal, whereas the short tail KIRs generate an activation
signal. The inhibitory signal results from the presence of
immunoreceptor tyrosine-based inhibition motifs (ITIMs) in the
cytoplasmic domains of the long tail receptors. The short tail
receptors owe their activating signals to their association with
adaptor proteins bearing immunoreceptor tyrosine-based activating motifs (ITAMs) (Figure 2). Whereas KIRs are specific for a number of
MHC class I molecules, HLA-C is the predominant class I isotype involved in the inhibitory and activating regulation of human NK cells
to provide either protection from or induction of target cell lysis and
cytokine production. For the purposes of our discussion, we will focus
on KIR recognition of HLA-C class I ligands. A current listing of known
KIRs and their known ligands can be found in Table
1.
A single KIR recognizes determinants that are shared between members of
a group of HLA-C alleles. Two HLA-C allotype groups are identified
according to amino acid residues present at positions 77 and 80 in the
Importantly, the number and role of inhibitory KIRs in NK cell biology
are still evolving.48 A few additional inhibitory KIRs are
listed in Table 1 with their respective ligands, when known. It appears
clear that corresponding inhibitory KIRs to many HLA-A and HLA-B
alleles do not exist, indicating that the KIR repertoire is not all
inclusive for human classical class I allotypes.49 One
long cytoplasmic tail KIR, KIR2DL4, recognizes the nonclassical MHC
class I allele HLA-G.50,51 HLA-G is a molecule that
displays limited polymorphism, and its expression has a unique
restricted tissue distribution on fetal extravillous trophoblasts that
invade the maternal decidua during pregnancy.52 In
contrast to other KIRs that are clonally distributed, KIR2DL4 is
thought to be expressed by all NK cells,51,53 although one study found that only decidual NK cells (all of which are
CD56bright) expressed this receptor and that peripheral
blood NK cells did not express KIR2DL4.54 Although
initially classified as an inhibitory receptor because of the presence
of ITIM in its cytoplasmic domain, recent evidence indicates that
ligation of KIR2DL4 on resting NK cells results in activation with the
unique property of inducing IFN- Another group of inhibitory receptors belongs to the immunoglobulin
superfamily and is represented by the immunoglobulinlike transcripts
(ILTs), also referred to as leukocyte immunoglobulinlike receptors
(LIRs).57,58 These receptors are encoded by a series of
genes on chromosome 19, close to the region encoding KIR. ILT receptors
are expressed primarily on myeloid cells, dendritic cells, and B
cells.57 ILT-2 (LIR-1) is also expressed on NK cells and
interacts directly with a broad spectrum of HLA class I molecules,
including HLA-G.57-59
A second family of human NK receptors is structurally
characterized by C-type lectin extracellular domains and is expressed as heterodimers composed of a common subunit (CD94) covalently bonded
to a distinct chain encoded by a gene of the C-type lectin NKG2
family.49,60-63 CD94 is a product of a single
nonpolymorphic gene and essentially lacks a cytoplasmic domain for
intrinsic signal transduction capacity.64 The
extracellular and cytoplasmic domains of the NKG2 molecules are
structurally diverse, consistent with differences in ligand recognition
and signal transduction.65-67 Homodimers of CD94 exist and
are of uncertain physiologic function.68 Four closely
related transcripts of the NKG2 family, with corresponding genes, have
been identified: NKG2A (and its splice variant NKG2B), NKG2C, NKG2E
(and its splice variant NKG2H), and NKG2F.65-67,69 NKG2D
is a fifth distantly related member that displays only a low sequence
similarity with the other NKG2 members and does not interact with CD94
(discussed later). The CD94 and NKG2
genes are all closely linked on chromosome 12p12.3-p13.1 in the human NK gene complex.69,70
CD94/NKG2 heterodimers are selectively expressed by NK cells and
cytotoxic T lymphocytes.71 Of the C-type lectin NK
receptors, only CD94/NKG2A is inhibitory, whereas other heterodimers
are activating receptors (Tables 1 and
2). NK clones may selectively bear either
inhibitory or activating CD94/NKG2 receptors, yet NKG2A and NKG2C can
be detected by revere transcription polymerase chain reaction (RT-PCR)
in some NK clones, and indirect functional data suggest that a subset
of NK cells may coexpress both receptors.68 The inhibitory
receptor CD94/NKG2A complex binds the nonclassical class I molecule
HLA-E.72-74 Interestingly, HLA-E binds leader peptides
derived from HLA-A, -B, -C, and -G, and, therefore, CD94/NKG2A functionally senses overall expression of HLA class I molecules at the
cell surface. For the same peptide/HLA-E complex, binding to the
inhibitory receptor CD94/NKG2A is stronger than binding to the
activating receptor CD94/NKG2C.75
Only when loaded with the appropriate nonamer peptides derived from the signal sequences of classic class I MHC molecules can the HLA-E molecule be transported to the cell surface.72-74 The detection of HLA-E by the CD94/NKG2 receptors may therefore be a sensitive mechanism for the immunosurveillance for normal biosynthesis of HLA class I molecules, a process that can be altered in virally infected or tumor cells. In addition, the ability of CD94/NKG2 receptors to discriminate among different peptide/HLA-E complexes might also influence reactivity against allogeneic cells. The spectrum of HLA molecules covered by KIRs and, indirectly, by CD94/NKG2 receptors, is only partially overlapping, suggesting that both systems play a complementary role for monitoring the biosynthesis/expression of most HLA class I molecules.76 The relative importance of each system and their interaction in modulating the reactivity of NK cells against autologous virus-infected and transformed cells, or allogeneic cells, remains to be elucidated. The biologic significance for the existence of paired inhibitory and activating receptors for MHC class I remains unclear. In both cases of KIRs and CD94/NKG2 receptors, the affinity of the activating receptor is lower than that of the corresponding inhibitory receptor,47,77 ensuring a predominance of the inhibitory signal when both activating and inhibitory receptors recognizing HLA molecules are expressed on the same NK cells. However, only a minority of NK cell clones express both activating and inhibitory isoforms that recognize the same HLA allotype.48,53,78 Much more commonly, NK cell clones expressing an activating receptor coexpress at least one inhibitory receptor specific for a different HLA class I allele that, when engaged, predominates. Therefore, the MHC class I-specific activating receptors may only signal when target cells have lost the expression of an HLA allele recognized by the inhibitory receptor, thus allowing NK cells' activating receptor to engage its ligand. In this way, NK cell surveillance may be important for removal of cells that have down-regulated or lost a single MHC class I allele while normal cells would be left unaffected.79 For example, virus-infected or transformed cells may selectively down-regulate HLA-A and -B allotypes while leaving HLA-C and -E unaffected.80,81 In this and other instances, positive target cell recognition by activating receptors is also essential to triggering NK cell cytotoxicity, and the balance between opposite signals delivered by inhibitory and/or activating receptors regulates NK cell functions. Activating receptors can be broadly grouped into those that are counterparts of the inhibitory receptors that recognize MHC class I molecules (discussed earlier) and those that do not have inhibitory counterparts and recognize inducible non-MHC molecules on target cells (Table 2).
Although the activating KIRs and CD94/NKG2 receptors may be
important in mediating NK cytotoxicity against MHC class I-bearing targets, other activating receptors are important in mediating cytotoxicity against MHC class I-deficient or negative targets. A
number of activating receptors with no apparent specificity for MHC
class I molecules have been reported, although many act as coactivators
rather than direct stimulators of NK cell function. In humans, a group
of receptors called natural cytotoxicity receptors (NCRs)82-86 and the NKG2D receptor have emerged as
activating receptors important in recognizing tumor cells in an
MHC-independent manner. Three NCRs (NKp46, NKp44, and NKp30) have been
identified. NKp46 and NKp30 are constitutively expressed by all
peripheral blood NK cells and are not found on other immune
cells.82,86 NKp44 is not expressed by resting NK cells but
is up-regulated on NK cells after IL-2 stimulation84 and
may be important for the cytotoxicity of IL-2-activated NK cells.
NKp44 is also found on a proportion of
The NKG2D is the best characterized activating receptor described
on NK cells. It is a C-type lectin surface receptor that is
misleadingly named as a member of the NKG2 family, encoded within the
NK gene complex on human chromosome 12.66,69,70 Unlike the
other NKG2 proteins presented earlier, NKG2D has little sequence
homology and does not associate with CD94 but is expressed as a
homodimer.88 The surface expression of NKG2D requires
association with a newly described adaptor subunit designated
DAP1088 or KAP10.89 The intracellular domain
of NKG2D does not have any signaling motif, and, therefore, signaling
is exclusively through its association with DAP10, which does not
contain a cytoplasmic ITAM but recruits phosphatidylinositol (PI)-3
kinase after phosphorylation that, in turn, induces cytotoxicity.
Importantly, because NKG2D has a signaling pathway that is distinct
from the activating KIR and C-type lectin NKR described earlier,
triggering via NKG2D is likely less susceptible to signals mediated by
inhibitory receptors. NKG2D is constitutively expressed by all NK cells
but is also expressed by almost all human
In contrast to the NCRs, target cell ligands for NKG2D have been identified and are induced by "stress" or neoplastic transformation, suggesting that NKG2D mediates the killing of cells that have been altered by these processes. The expression of these ligands may, therefore, be signals of "altered self" or "danger" to the innate immune system to promote NK and T-cell responses. In the human, these recently defined ligands belong to 2 distinct families, the MHC class I chain-related (MIC) antigens, and the UL16 binding proteins (ULBPs).91-94 The MIC antigens are encoded by a distinct family of genes stationed
along the entire MHC class I region on human chromosome 6. They have a
low degree of homology to other MHC-encoded class I genes, distinct
transcriptional control elements, and a peculiar pattern of
polymorphism.91 There are 7 MIC loci,
A to G, but only the MICA and
MICB genes are transcribed; MIC-C, -D, -E, -F and -G are pseudogenes.91-93 The MIC
glycoproteins contain 3 MHC-like Unlike MHC class I, MIC genes are not ubiquitously expressed. Bahram91 and Shiina et al92 have demonstrated that MIC transcripts are not expressed in the spleen and cells of the lympho-hematopoietic lineage, although they are expressed in fibroblast and epithelial cell lines as well as almost all tissues harboring these cell types. The expression of MICA and MICB are under the control of promoter elements similar to those of the heat shock protein gene PSP70.96 In this respect, exposure of MIC-expressing epithelial lines to heat shock was shown to increase expression of MIC transcripts and proteins.96 Furthermore, MIC expression on fibroblasts and epithelial cells was strongly up-regulated following infection with cytomegalovirus (CMV).97 Importantly, high MICA and MICB expression was detected on many human epithelial tumors98,99 and more recently on the JA3 and Raji leukemic cell lines,98 as well as on primary acute myeloid leukemia (AML) blasts (S.S.F., T.A.F., and M.A.C., unpublished observations, February 2002). Therefore, induction or up-regulation of MIC expression may occur with cellular stress, viral infection, or neoplastic transformation and may facilitate attack of these altered cells by NK cells and some T cells. The second family of NKG2D ligands reported are human cellular
proteins, initially identified by their ability to bind the human CMV
protein UL16, which is a type I transmembrane protein known to be
expressed by CMV-infected cells.100 UL16 binds to MICB and
2 proteins designated ULBP-1 and ULBP-2.94 By
expression-cloning a third member of this family of proteins has been
reported, ULBP-3, that, however, does not bind UL16.94 The
3 ULBPs possess The expression of ULBPs is more widespread than that of MIC proteins. With the use of RT-PCR, ULBP transcripts were detected in heart, lung, testis, brain, lymph nodes, thymus, tonsil, liver, and bone marrow.94 However, in some tissues where high ULBP mRNA expression was detected, no cell surface expression was found by monoclonal antibody,94 suggesting that surface expression of ULBPs may be regulated at a posttranscriptional level. This finding has important implications for the study of these ligands in tumor cell recognition by NK cells.
The relative role of NCR (NKp46, NKp44, and NKp30) and NKG2D in the lysis of various tumors by human NK cell clones has been recently analyzed. Pende et al98 demonstrated that, although lysis of certain tumor cell lines was exclusively NCR dependent, killing of other tumor types, including melanoma and leukemia cell lines, involved synergism between NCR and NKG2D.98 With the use of NCRdull NK cell clones, it was also demonstrated that in some cases NKG2D was the only triggering receptor responsible for tumor cell lysis. Surface density expression of NKG2D on both NCRbright and NCRdull NK cell clones was equivalent.98 Therefore, the functions of NCR, whose ligands are unknown, and NKG2D appear to be complementary and depend on ligand expression by the tumor cells. To date, most studies have been performed by using tumor cell lines, and little investigation of the interaction between activation receptors and primary tumor cells has been conducted. The extent to which activation of NK cells through NKG2D can be prevented by inhibitory signals from MHC class I-recognizing inhibitory receptors is not yet fully resolved. As mentioned earlier, the affinity of inhibitory KIRs and CD94/NKG2 receptors for their MHC class I ligands is significantly higher that that of their activating counterparts, suggesting that inhibitory signals predominate. NCR-dependent lysis of autologous cells appears to require blocking of inhibitory receptors by anti-HLA class I monoclonal antibodies, similarly suggesting that the inhibitory signal may normally predominate.83 In contrast, the activating signal through NKG2D may override the inhibitory signaling mediated by MHC class I molecules both ex vivo90,94 and in vivo in a mouse model.102 The basis of the mechanism for this observation is not known but may be related to a higher affinity of NKG2D for its ligands.103 The overriding effect of NKG2D-mediated activating signal, however, was not confirmed in studies by Pende et al,98 who showed that the engagement of different HLA class I-specific inhibitory receptors by either specific antibodies or the appropriate HLA class I ligand led to inhibition of NKG2D-mediated NK cell triggering. Of note, this effect was observed when normal cells (phytohemagglutinin [PHA] blasts) or the ovarian tumor cell line, IGROV-1, expressing high densities of HLA class I molecules, were used.98 It is, therefore, likely that NK cell killing of tumor cells is the result of integration of signals from several activating and inhibitory receptors that are regulated by the density and selection of class I and class I-like ligands expressed by the target cell (Figure 1C,D). In this respect, it is not known to what extent exogenously administered cytokines, such as IL-2 and IL-12, may modulate effector cell NKR and ligand expression on target cells in vivo.
A number of other receptor molecules have been implicated in the process of triggering of NK cell-mediated cytotoxicity. In redirected killing assay using monoclonal antibodies that initiate killing of Fc receptor-bearing tumor cell lines, NK cell surface molecules that have been implicated in cell activation include CD2,104 CD16,105 LFA-1,106 CD40 ligand,107 CD69,108 2B4,109-111 and NKp80.112,113 These receptors, however, function as coreceptors in that their triggering function depends on the simultaneous ligation of main triggering receptors. For example, monoclonal antibody triggering via the 2B4 and NKp80 molecules induces strong cytolytic responses only in NKp46bright NK cells but not in NKp46dull cells, although the latter expressed comparable surface densities of 2B4 and NKp80.111,112 Therefore, these coreceptors only result in activation if a first signal has been provided by the main receptor. The relative roles of these coreceptors in NK-mediated killing of tumor cells remains to be fully elucidated.
Previous strategies using NK cells for the treatment of human malignancy have been largely restricted to the use of ex vivo generated lymphokine-activated killer (LAK) cells or activated NK cells114-116 or in vivo cytokine therapy to expand and activate NK cells against autologous cancer cells.9,117-120 In most studies, it has been difficult to convincingly demonstrate a clinical benefit, especially in small phase I and II clinical trials. Although it is not known to what extent cytokines, such as IL-2, may alter the balance between activating and inhibitory receptors on NK cells, it is likely that the inhibitory signals delivered by MHC class I molecules expressed on the autologous target cancer are a major limitation to successful treatment. Strategies aimed at either using the mismatch of receptors and ligands that is present in certain allogeneic settings, or blocking the interaction between inhibitory NK cell receptors and MHC class I molecules, may be more successful.
The cure of refractory leukemia and other hematologic malignancies following allogeneic stem cell transplantation has been largely attributable to the ability of donor immune cells in the graft to recognize and eliminate neoplastic cells that have escaped killing by high-dose chemotherapy. Moreover, following minimally myeloablative transplants or donor lymphocyte infusion (DLI), this GVL effect is the only mechanism by which leukemic cells are eliminated. Immune cells infused in the graft or the DLI exert a GVL effect through T-cell-mediated alloreactions directed against host minor or major histocompatibility antigens, depending on the extent of MHC mismatching between donor and recipient. In humans, it has been difficult to demonstrate a role for NK cells in mediating a GVL effect in MHC-matched transplants. T-cell depletion of stem cell grafts, to reduce the risk of graft-versus-host disease (GVHD), has been associated with a significantly increased risk of relapse, particularly in patients with chronic myeloid leukemia.1,121 In the full haplotype-mismatched setting, however, NK cells have recently been demonstrated to exert an important GVL effects.122 In full haplotype-mismatched stem cell transplantation, in which donors
and recipient pairs are identical for one HLA haplotype and
incompatible at the HLA class I and II loci of the unshared haplotype,
all cases are at risk of T-cell-mediated alloreactions in the
host-versus-graft (HvG) and graft-versus-host (GvH) direction. These
T-cell-mediated reactions can be eliminated to a large extent by
altering the immunosuppressive intensity of the conditioning regimen to
prevent rejection by and extensive T-cell depletion of the graft to
prevent GVHD. However, another level of alloreactivity is provided by
mismatches at the KIR epitopes expressed by HLA class I alleles, as
shown in Figure
4. Recall
from earlier that certain KIRs recognize a variety of HLA class I
alleles belonging to a specific group, even if the NK cell itself does
not express those alleles. Further, inhibitory KIRs will predominate
over activating KIRs.
Individuals who are homozygous for group 2 HLA-C alleles generate NK
cells with KIRs that recognize group 2 HLA-C alleles, eg, KIR2DL1 and
KIR2DS1, and individuals who are homozygous for group 1 HLA-C alleles
generate NK cells with KIRs that recognize group 1 HLA-C alleles, eg,
KIR2DL3 and KIR2DS3.123 In this way, an individual's NK
cell compartment inspects host tissues, engages HLA-C class I ligands
through inhibitory KIRs with greater affinity than activating KIRs and,
consequently, maintains natural immunologic tolerance and avoids
autoimmunity. However, the same can be true of NK allorecognition, if
the HLA-C allele on the allogeneic target cell belongs to the group
with the same shared determinants in the Note that the donor in Figure 4A has one HLA-C haplotype encoding a group 2 HLA-C allele (eg, HLA-Cw2) and another haplotype encoding a group 1 HLA-C allele (eg, HLA-Cw3), such that all nucleated cells in this individual express a group 1 and group 2 HLA-C class I allele. Can there be autologous NK killing of normal tissue? KIRs are clonally distributed, so, in this instance, each of that individual's NK cells will have at least one inhibitory KIR recognizing either the group 1 (eg, KIR2DL2) or group 2 (eg, KIR2DL1) HLA-C allele but not necessarily both.53 Self-tolerance is preserved, because the NK cell always engages at least one ligand for its inhibitory KIR as it performs immune surveillance of its own normal cells, each of which will express the full complement of the genotype (in this case, both a group 1 and a group 2 HLA-C allele). Thus, some NK clones from this individual will express KIR2DL1 and will have cytolytic potential against allogeneic target cells from a patient homozygous for group 1 HLA-C alleles (Figure 4A), whereas other NK clones from the same individual will express KIR2DL2 or KIR2DL3 and will have cytolytic potential against allogeneic target cells from a patient homozygous for group 2 HLA-C alleles (not shown). However, each of these NK clones will not be able to lyse allogeneic target cells that coexpressed group 1 and 2 HLA-C alleles (Figure 4B). These differences have been validated in vitro,123,124 lending additional insight into the potential role of NK cells in eradicating host lymphohematopoietic cells, including leukemia, following T-cell-depleted haplotype-mismatch hematopoietic transplantation. In haplotype-mismatch hematopoietic transplantation, donor NK cell clones not engaging their class I inhibitory KIR ligands or members of their group class I alleles in the recipient, in the setting in which the donor and recipient are also mismatched at the HLA class I group, are expected to display alloreactivity against host leukemic cells. Conversely, if class I group mismatch is not present, despite the haplotype-mismatch, donor NK cells will be inhibited by their inhibitory KIR ligands and no alloreactivity is expected. This finding has been recently confirmed by Ruggeri et al,122 who isolated donor-versus-recipient alloreactive NK cell clones from donor blood, capable of lysing recipients' PHA lymphoblasts or EBV-transformed B-lymphoblastoid cell line obtained prior to transplantation in all tested donor-recipient pairs KIR epitope-mismatched in the GvH direction.122 In addition, following transplantation of T-cell-depleted stem cells, the engrafted stem cells rapidly gave rise to a transient wave of reconstituting NK cells whose KIR repertoire was identical to that originally displayed by the donor, including high-frequency donor-versus-recipient alloreactive NK clones.122 Importantly, donor-derived alloreactive NK cell clones could not be isolated from the recipient's blood beyond 4 months after transplantation, indicating that deletion of "self-reactive" NK cells or induction of anergy in these cells occurred.122 Although the persistence of alloreactive NK cell clones was transient, a remarkable GVL effect was observed in patients with acute myeloid leukemia at high risk of relapse (15% of patients were in second complete remission, and 85% were in third or more complete remission or in relapse).125 Patients were conditioned with total body irradiation (800 cGy), thiotepa, antithymocyte globulin, and fludarabine (or cyclophosphamide) and were transplanted with T-cell-depleted granulocyte colony-stimulating factor-mobilized peripheral blood cells (15 ± 5 × 106 CD34+ cells/kg and < 4 × 104 CD3+ cells/kg). No posttransplantation GVHD prophylaxis was administered. When KIR epitope-mismatch in the GvH direction was not present, the probability of relapse at 5 years was 75% in the face of intensive pretransplantation conditioning regimen, compared with 0% when KIR epitope-mismatch in the GvH direction was present.125 In addition, whereas rejection and grade II or greater acute GVHD rates were 15.5% and 13.7%, respectively, in the first group, they were 0% for both in the second. Thus, in AML the probability of survival at 5 years was 5% without KIR ligand incompatibility in the GvH direction and 60% with it. The latter is considerably better than survival reported by the National Marrow Donor Program after matched unrelated-donor transplant in adult patients in the same risk category (27% in second complete remission; 7% in third or more complete remission or in relapse). Remarkably, it is also better than the 35% survival reported in patients transplanted in first complete remission.126 In the remaining 40% of patients, death was caused by infection. The advanced stage of disease at transplantation largely accounted for such infection-related mortality. Indeed, the probability of survival of patients transplanted in remission, with KIR ligand incompatibility in the GvH direction, was 80% (A.V., unpublished observations, December 2001). Although the data from Perugia emphasize the important role for KIR inhibitory receptors in haplotype-mismatched stem cell transplants,122 the role of activating NK cells receptors has not been studied. In this respect, it is important to note that, although myeloid leukemias were susceptible to NK lysis when KIR epitope mismatches were found, blasts from patients with acute lymphoblastic leukemia (ALL) were resistant, and a high relapse rate was observed in patients with ALL. Immunofluorescence analysis of several adhesion molecules showed that NK-resistant ALL blasts exhibited lower surface expression of lymphocyte function antigen-1 (LFA-1), an adhesion molecule instrumental to binding of NK cells to their targets, compared with NK-susceptible ALL blasts, and leukemic myeloblasts.122 However, it is also possible that a difference in expression of activating ligands between ALL and myeloid leukemia also exists. Systematic studies of the expression levels of the known activating ligands, MICA and MICB, and ULBP-1, -2, and -3 on primary leukemic cells are lacking. Although MICA and MICB expression have been demonstrated on the T-cell leukemia cell line JA3, and MICA on the Burkitt lymphoma cell line Raji,98 there are no published reports investigating the expression on primary lymphoblasts. We have begun investigating the expression of activating ligands on leukemic blasts and detected MICA and/or MICB transcripts in myeloblasts of 6 of 8 AML cases (S.S.F., T.A.F., and M.A.C., unpublished data, February 2002). This type of analysis, however, is limited by the fact that not all ligands for the activating NK receptors are known. Ligands for the NCRs have not yet been identified, and it is likely that there are more ligands for NKG2D than are currently known. The role of other MIC alleles as ligands for NK receptors is unknown, and the possibility exists that other proteins of the ULBP family may also act as activating ligands. The development of an NKG2D-immunoglobulin fusion protein should facilitate the investigation of the cellular distribution of ligands and the identification of other potential ligands for this receptor. Another important result of the Perugia study122,125 is absence of GVHD despite the strong antileukemic effect by donor-versus-recipient alloreactive NK cell clones. A similar phenomenon of "hybrid resistance" is seen in murine transplantation models, in which host F1 mouse NK cells reject parental bone marrow cells but tolerate parental skin and organ grafts.127 It has been presumed that nonhematopoietic tissues lack the necessary ligands to bind and/or activate NK cells. In this respect, it is of note that the stress-inducible activating ligands for NKG2D, MICA, and MICB, are not highly expressed on normal epithelial tissues usually involved in GVHD. In contrast, although ULBP transcripts have been detected in epithelial cells, the extent of surface expression of these molecules is unknown. It is, therefore, possible that differential expression of these activating ligands on hematopoietic and nonhematopoietic tissues may explain the observed GVL in the absence of GVHD. Further evidence comes from mouse transplant models. Infusion of allogeneic NK cells (presumably containing NK cells not recognizing recipient MHC) has not been associated with the development, but sometime associated with suppression, of GVHD.128-130 The Perugia study125 directly addressed this point by infusing high numbers of purified host-reactive NK cells into lethally irradiated mice.125 No GVHD whatsoever was observed. On the contrary, the infusion of alloreactive NK cells actually prevented GVHD by killing host antigen-presenting cells, thus allowing the safe add-back of 20 times the lethal dose of allogeneic T cells for immune reconstitution. Indeed, in clinical hematopoietic stem cell transplantation KIR epitope incompatibility in the GvH direction not only did not cause GVHD but also was totally protected from it (see earlier). Should the pretransplantation infusion of alloreactive NK cells become feasible in humans, more T cells could safely be given with the graft, thus greatly improving the efficacy of haplotype-mismatched transplants. As is well known, the T-cell depletion, which is currently needed to prevent GVHD, leads to poor immune reconstitution and infection-related mortality.
Evidence that NK cell alloreactivity does not target tissues other than lymphohematopoietic cells suggested the pretransplantation infusion of alloreactive NK cells might be safely used to condition the host to transplantation. To test this finding, Ruggeri et al125 reversed the hybrid resistance transplantation partners, such that NK reactivity was now in the GvH direction. They showed that infusion of hybrid H-2d/b mouse NK cells, reactive against the homozygous host H-2b/b cells, into nonlethally irradiated H-2b/b recipients allowed the engraftment of H-2d/b bone marrow cells.125 In the absence of the alloreactive hybrid H-2d/b mouse NK cell infusion, nonlethally irradiated H-2b/b mice rejected the donor bone marrow and recovered uneventfully. These experiments indicate that alloreactive NK cells in the GvH direction can themselves promote sufficient immune suppression and myeloablation to allow engraftment of MHC disparate bone marrow, without development of GVHD, using a nonlethal preparative regimen. If this finding can be translated into the clinic, it would permit the extension of nonmyeloablative transplantation to the haplotype-mismatched setting without needing to severely immunosuppress the recipient to prevent rejection of donor stem cells. Given the relatively low dose of alloreactive NK cells required for this effect, translation of these experiments to the clinic should be considered, particularly in light of the retrospective clinical observation that transplantation with KIR epitope incompatibility in the GvH direction and the ensuing spontaneous generation of alloreactive NK cells totally controls rejection.
Another potential therapeutic strategy is blocking the interaction between KIR inhibitory receptors and their MHC class I ligands. In the autologous and HLA-matched setting, expression of MHC class I molecules by leukemic cells might confer resistance to NK cell-mediated lysis. Koh et al131 have recently used a murine acute leukemia model to demonstrate that in vivo NK cell inhibitory receptor blockade is feasible. Treatment of B6 mice, injected with C1498 (H2d) murine leukemia cells, with 5E6 F(ab')2 anti-Ly49C and I (murine counterparts of inhibitory NK receptors) protected them from leukemic death without toxicity or effects on hematologic parameters.131 In contrast, control mice treated with vehicle died of leukemia. In further experiments, adoptive transfer of IL-2-activated NK cells treated with 5E6 F(ab')2 ex vivo protected mice from leukemic death, compared with transfer of untreated IL-2-activated NK cells. This study provides strong rationale to pursue translational research in inhibitory receptor blockade, noting the increased complexity in the human system. As only certain subsets of NK cells express inhibitory receptors that recognize specific self-MHC molecules, simultaneous blockade of several receptors, including CD94/NKG2, may provide even greater antileukemic effects. In addition to in vivo therapy with blocking antibodies, extension of this approach to ex vivo purging of autologous stem cell products by coculture of stem cell preparations with activated NK cells in the presence of F(ab')2 fragments directed toward inhibitory receptors has also been suggested.132 The susceptibility of human CD34+ cells to lysis by alloreactive NK cells, however, may limit this approach.133 Alternatively, NK inhibitory receptor blockade may be applied to enhance immune responses to viral infections, such as CMV, which encodes a MHC class I homologue to evade the innate immune system. Clinical trials of receptor blockade are awaited and will provide a novel approach to immunotherapy of leukemia.
As discussed earlier, it appears that the response of NK cells depends on the balance between triggering and inhibitory signals mediated through corresponding activating and inhibitory receptors. An alternative approach to altering this balance in favor of activation may be the induction of activating receptor expression on NK cells through the use of cytokines. Few studies have examined this issue to date. It is known, for example, that IL-2 induces the natural cytotoxicity receptor, NKp44, which is not found on resting NK cells.84 The effect of cytokines on expression of other NK cell receptors is not well studied. Preliminary reports suggest that expression density of NCR may be stable and not influenced by IL-2, IL-15, IL-12, and IL-18.35 No data are available on the effect of cytokines on NKG2D expression density. However, as it is known that activated NK cells are more effective at lysing targets that are resistant to nonactivated NK cells, it would seem reasonable to more fully study the differences in the pattern of NK receptor and coreceptor expression with cytokine activation. An ability to manipulate the balance of activating and inhibitory receptors on NK cells may open new avenues in immunotherapy. Along the same lines, understanding the regulation of activating ligands on leukemic cells may allow development of strategies directed at increasing expression of these ligands, possibly in combination with activated NK cell therapy.
The past decade has witnessed a virtual explosion in our knowledge of NK cell receptors. It is now appreciated that NK cell responses are a result of competing signals mediated through inhibitory and activating receptors. Although in physiologic situations, inhibitory signals through the interaction of KIR and CD94/NKG2A receptors with MHC class I molecules appear to dominate, in other situations, the balance may be altered in favor of NK cell triggering. Appreciation of this concept has already led to the successful use of the antileukemic potential of NK cells through KIR-epitope mismatches in the setting of haplotype-mismatched stem cell transplantation. The benefits of NK cell alloreactivity, ie, ablation of leukemia and improved prevention of rejection and GVHD, are already a reality in high-risk patients with AML who receive HLA haplotype-mismatched transplants after high-intensity conditioning regimens. Preclinical models show NK cell alloreactivity could make reduced-intensity conditioning mismatched transplants available to patients with leukemia who cannot withstand the toxicity of current regimens. Clinical trials, using KIR-epitope mismatched NK cells to facilitate engraftment of mismatched stem cells with reduced intensity conditioning, and NK cell inhibitory receptor blockade are eagerly awaited. Over the forthcoming decade, it is expected that translation of our improved knowledge of NK cell biology and receptors will lead to advancements in cancer immunotherapy.
Submitted February 4, 2002; accepted April 11, 2002.
Prepublished online as Blood First Edition Paper, April 30, 2002; DOI 10.1182/blood-2002-02-0350.
Supported by grants CA68458, CA65670, and P30CA16058 from the National Institutes of Health. T.A.F. is the recipient of Medical Scientist Program (MSP) and Bennett fellowships from The Ohio State University College of Medicine and Public Health. A.V. is supported by grants from the Italian Association for Cancer Research (AIRC), the Italian Ministry of Research (MURST), the Italian Ministry of Health, and by a Translational Research Grant from the Leukemia & Lymphoma Society.
Reprints: Sherif S. Farag, The Ohio State University, A433A Starling Loving Hall, 320 W Tenth Ave, Columbus, OH 43210; e-mail: farag-1{at}medctr.osu.edu.
1.
Horowitz MM, Gale RP, Sondel PM, et al.
Graft-versus-leukemia reactions after bone marrow transplantation.
Blood.
1990;75:555-562
2.
Collins RH Jr, Shpilberg O, Drobyski WR, et al.
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
J Clin Oncol.
1997;15:433-444 3. Yee C, Riddell SR, Greenberg PD. Prospects for adoptive T cell therapy. Curr Opin Immunol. 1997;9:702-708[CrossRef][Medline] [Order article via Infotrieve]. 4. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380-384[CrossRef][Medline] [Order article via Infotrieve].
5.
Robertson MJ, Ritz J.
Biology and clinical relevance of human natural killer cells.
Blood.
1990;76:2421-2438 6. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187-376[Medline] [Order article via Infotrieve]. 7. Thompson JA, Shulman KL, Benyunes MC, et al. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J Clin Oncol. 1992;10:960-968[Abstract]. 8. Caligiuri MA, Murray C, Robertson MJ, et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest. 1993;91:123-132[Medline] [Order article via Infotrieve].
9.
Soiffer RJ, Murray C, Gonin R, Ritz J.
Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation.
Blood.
1994;84:964-971 10. Cooper MA, Fehniger TA, Caligiuri MA. Biology of human natural killer cell subsets. Trends Immunol. 2001;22:633-640[CrossRef][Medline] [Order article via Infotrieve]. 11. Lotzova E, Savary CA, Herberman RB. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol. 1987;138:2718-2727[Abstract].
12.
Oshimi K, Oshimi Y, Akutsu M, et al.
Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells.
Blood.
1986;68:938-948 13. Allavena P, Damia G, Colombo T, Maggioni D, D'Incalci M, Mantovani A. Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agents. Cell Immunol. 1989;120:250-258[CrossRef][Medline] [Order article via Infotrieve].
14.
Landay AL, Zarcone D, Grossi CE, Bauer K.
Relationship between target cell cycle and susceptibility to natural killer lysis.
Cancer Res.
1987;47:2767-2770
15.
Cooper MA, Fehniger TA, Turner SC, et al.
Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.
Blood.
2001;97:3146-3151
16.
Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J.
Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors.
J Exp Med.
1990;171:1509-1526 17. Baume DM, Robertson MJ, Levine H, Manley TJ, Schow PW, Ritz J. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. Eur J Immunol. 1992;22:1-6[Medline] [Order article via Infotrieve]. 18. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol. 1989;143:3183-3191[Abstract]. 19. Ellis TM, Fisher RI. Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells. J Immunol. 1989;142:2949-2954[Abstract].
20.
Robertson MJ, Soiffer RJ, Wolf SF, et al.
Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF.
J Exp Med.
1992;175:779-788
21.
Voss SD, Daley J, Ritz J, Robertson MJ.
Participation of the CD94 receptor complex in costimulation of human natural killer cells.
J Immunol.
1998;160:1618-1626
22.
Andre P, Spertini O, Guia S, et al.
Modification of P-selectin glycoprotein ligand-1 with a natural killer cell-restricted sulfated lactosamine creates an alternate ligand for L-selectin.
Proc Natl Acad Sci U S A.
2000;97:3400-3405
23.
Fehniger TA, Caligiuri MA.
Interleukin 15: biology and relevance to human disease.
Blood.
2001;97:14-32
24.
Yu H, Fehniger TA, Fuchshuber P, et al.
Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15.
Blood.
1998;92:3647-3657 25. Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol. 2001;19:291-330[CrossRef][Medline] [Order article via Infotrieve].
26.
Miller JS, McCullar V.
Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2.
Blood.
2001;98:705-713 27. Ljunggren HG, Karre K. In search of the `missing self': MHC molecules and NK cell recognition. Immunol Today. 1990;11:237-244[CrossRef][Medline] [Order article via Infotrieve].
28.
Storkus WJ, Alexander J, Payne JA, Dawson JR, Cresswell P.
Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes.
Proc Natl Acad Sci U S A.
1989;86:2361-2364 29. Shimizu Y, DeMars R. Demonstration by class I gene transfer that reduced susceptibility of human cells to natural killer cell-mediated lysis is inversely correlated with HLA class I antigen expression. Eur J Immunol. 1989;19:447-451[Medline] [Order article via Infotrieve].
30.
Zijlstra M, Auchincloss H Jr, Loring JM, Chase CM, Russell PS, Jaenisch R.
Skin graft rejection by beta 2-microglobulin-deficient mice.
J Exp Med.
1992;175:885-893 31. Routes JM. IFN increases class I MHC antigen expression on adenovirus-infected human cells without inducing resistance to natural killer cell killing. J Immunol. 1992;149:2372-2377[Abstract].
32.
Malnati MS, Lusso P, Ciccone E, Moretta A, Moretta L, Long EO.
Recognition of virus-infected cells by natural killer cell clones is controlled by polymorphic target cell elements.
J Exp Med.
1993;178:961-969 33. Lanier LL. Activating and inhibitory NK cell receptors. Adv Exp Med Biol. 1998;452:13-18[Medline] [Order article via Infotrieve]. 34. Lopez-Botet M, Bellon T. Natural killer cell activation and inhibition by receptors for MHC class I. Curr Opin Immunol. 1999;11:301-307[CrossRef][Medline] [Order article via Infotrieve]. 35. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197-223[CrossRef][Medline] [Order article via Infotrieve]. 36. Dohring C, Scheidegger D, Samaridis J, Cella M, Colonna M. A human killer inhibitory receptor specific for HLA-A1,2. J Immunol. 1996;156:3098-3101[Abstract].
37.
Pende D, Biassoni R, Cantoni C, et al.
The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer.
J Exp Med.
1996;184:505-518 38. Wagtmann N, Rajagopalan S, Winter CC, Peruzzi M, Long EO. Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and functional transfer. Immunity. 1995;3:801-809[CrossRef][Medline] [Order article via Infotrieve].
39.
Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL.
NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules.
J Exp Med.
1994;180:537-543
40.
Vitale M, Sivori S, Pende D, et al.
Physical and functional independency of p70 and p58 natural killer (NK) cell receptors for HLA class I: their role in the definition of different groups of alloreactive NK cell clones.
Proc Natl Acad Sci U S A.
1996;93:1453-1457
41.
Moretta A, Bottino C, Pende D, et al.
Identification of four subsets of human CD3
42.
Moretta A, Vitale M, Bottino C, et al.
P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities.
J Exp Med.
1993;178:597-604
43.
Biassoni R, Cantoni C, Falco M, et al.
The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions.
J Exp Med.
1996;183:645-650
44.
Colonna M, Samaridis J.
Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells.
Science.
1995;268:405-408 45. Selvakumar A, Steffens U, Palanisamy N, Chaganti RS, Dupont B. Genomic organization and allelic polymorphism of the human killer cell inhibitory receptor gene KIR103. Tissue Antigens. 1997;49:564-573[Medline] [Order article via Infotrieve]. 46. Wilson MJ, Torkar M, Trowsdale J. Genomic organization of a human killer cell inhibitory receptor gene. Tissue Antigens. 1997;49:574-579[Medline] [Order article via Infotrieve]. 47. Vales-Gomez M, Reyburn HT, Mandelboim M, Strominger JL. Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors. Immunity. 1998;9:337-344[CrossRef][Medline] [Order article via Infotrieve]. 48. Uhrberg M, Valiante NM, Shum BP, et al. Human diversity in killer cell inhibitory receptor genes. Immunity. 1997;7:753-763[CrossRef][Medline] [Order article via Infotrieve]. 49. Lanier LL. NK cell receptors. Annu Rev Immunol. 1998;16:359-393[CrossRef][Medline] [Order article via Infotrieve]. 50. Cantoni C, Verdiani S, Falco M, et al. p49, a putative HLA class I-specific inhibitory NK receptor belonging to the immunoglobulin superfamily. Eur J Immunol. 1998;28:1980-1990[CrossRef][Medline] [Order article via Infotrieve].
51.
Rajagopalan S, Long EO.
A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells.
J Exp Med.
1999;189:1093-1100 52. Loke YW, King A. Immunology of human placental implantation: clinical implications of our current understanding. Mol Med Today. 1997;3:153-159[CrossRef][Medline] [Order article via Infotrieve]. 53. Valiante NM, Uhrberg M, Shilling HG, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity. 1997;7:739-751[CrossRef][Medline] [Order article via Infotrieve].
54.
Ponte M, Cantoni C, Biassoni R, et al.
Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor.
Proc Natl Acad Sci U S A.
1999;96:5674-5679
55.
Rajagopalan S, Fu J, Long EO.
Induction of IFN-gamma production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in resting NK cells.
J Immunol.
2001;167:1877-1881
56.
Ashkar AA, Di Santo JP, Croy BA.
Interferon gamma contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy.
J Exp Med.
2000;192:259-270
57.
Colonna M, Navarro F, Bellon T, et al.
A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells.
J Exp Med.
1997;186:1809-1818 58. Cosman D, Fanger N, Borges L, et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity. 1997;7:273-282[CrossRef][Medline] [Order article via Infotrieve]. 59. Navarro F, Llano M, Bellon T, Colonna M, Geraghty DE, Lopez-Botet M. The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur J Immunol. 1999;29:277-283[CrossRef][Medline] [Order article via Infotrieve]. 60. Lazetic S, Chang C, Houchins JP, Lanier LL, Phillips JH. Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. J Immunol. 1996;157:4741-4745[Abstract]. 61. Carretero M, Cantoni C, Bellon T, et al. The CD94 and NKG2-A C-type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules. Eur J Immunol. 1997;27:563-567[Medline] [Order article via Infotrieve]. 62. Perez-Villar JJ, Carretero M, Navarro F, et al. Biochemical and serologic evidence for the existence of functionally distinct forms of the CD94 NK cell receptor. J Immunol. 1996;157:5367-5374[Abstract].
63.
Brooks AG, Posch PE, Scorzelli CJ, Borrego F, Coligan JE.
NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor.
J Exp Med.
1997;185:795-800 64. Chang C, Rodriguez A, Carretero M, Lopez-Botet M, Phillips JH, Lanier LL. Molecular characterization of human CD94: a type II membrane glycoprotein related to the C-type lectin superfamily. Eur J Immunol. 1995;25:2433-2437[Medline] [Order article via Infotrieve]. 65. Adamkiewicz TV, McSherry C, Bach FH, Houchins JP. Natural killer lectin-like receptors have divergent carboxy-termini, distinct from C-type lectins. Immunogenetics. 1994;39:218[Medline] [Order article via Infotrieve].
66.
Houchins JP, Yabe T, McSherry C, Bach FH.
DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells.
J Exp Med.
1991;173:1017-1020 67. Plougastel B, Jones T, Trowsdale J. Genomic structure, chromosome location, and alternative splicing of the human NKG2A gene. Immunogenetics. 1996;44:286-291[CrossRef][Medline] [Order article via Infotrieve]. 68. Lopez-Botet M, Carretero M, Bellon T, Perez-Villar JJ, Llano M, Navarro F. The CD94/NKG2 C-type lectin receptor complex. Curr Top Microbiol Immunol. 1998;230:41-52[Medline] [Order article via Infotrieve]. 69. Sobanov Y, Glienke J, Brostjan C, Lehrach H, Francis F, Hofer E. Linkage of the NKG2 and CD94 receptor genes to D12S77 in the human natural killer gene complex. Immunogenetics. 1999;49:99-105[CrossRef][Medline] [Order article via Infotrieve]. 70. Glienke J, Sobanov Y, Brostjan C, et al. The genomic organization of NKG2C, E, F, and D receptor genes in the human natural killer gene complex. Immunogenetics. 1998;48:163-173[CrossRef][Medline] [Order article via Infotrieve]. 71. Aramburu J, Balboa MA, Ramirez A, et al. A novel functional cell surface dimer (Kp43) expressed by natural killer cells and T cell receptor-gamma/delta+ T lymphocytes. I. Inhibition of the IL-2-dependent proliferation by anti-Kp43 monoclonal antibody. J Immunol. 1990;144:3238-3247[Abstract]. 72. Braud VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795-799[CrossRef][Medline] [Order article via Infotrieve].
73.
Lee N, Llano M, Carretero M, et al.
HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A.
Proc Natl Acad Sci U S A.
1998;95:5199-5204
74.
Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG.
Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis.
J Exp Med.
1998;187:813-818 75. Llano M, Lee N, Navarro F, et al. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol. 1998;28:2854-2863[CrossRef][Medline] [Order article via Infotrieve]. 76. Lopez-Botet M, Bellon T, Llano M, Navarro F, Garcia P, de Miguel M. Paired inhibitory and triggering NK cell receptors for HLA class I molecules. Hum Immunol. 2000;61:7-17[CrossRef][Medline] [Order article via Infotrieve]. 77. Vales-Gomez M, Reyburn HT, Erskine RA, Lopez-Botet M, Strominger JL. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J. 1999;18:4250-4260[CrossRef][Medline] [Order article via Infotrieve]. 78. Cantoni C, Biassoni R, Pende D, et al. The activating form of CD94 receptor complex: CD94 covalently associates with the Kp39 protein that represents the product of the NKG2-C gene. Eur J Immunol. 1998;28:327-338[CrossRef][Medline] [Order article via Infotrieve]. 79. Bakker AB, Wu J, Phillips JH, Lanier LL. NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. Hum Immunol. 2000;61:18-27[CrossRef][Medline] [Order article via Infotrieve]. 80. Marincola FM, Shamamian P, Alexander RB, et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol. 1994;153:1225-1237[Abstract]. 81. Cohen GB, Gandhi RT, Davis DM, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity. 1999;10:661-671[CrossRef][Medline] [Order article via Infotrieve].
82.
Sivori S, Vitale M, Morelli L, et al.
p46, a novel natural killer cell-specific surface molecule that mediates cell activation.
J Exp Med.
1997;186:1129-1136 83. Pessino A, Sivori S, Bottino C, et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med. 1998;188:953-960[CrossRef][Medline] [Order article via Infotrieve].
84.
Vitale M, Bottino C, Sivori S, et al.
NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis.
J Exp Med.
1998;187:2065-2072
85.
Cantoni C, Bottino C, Vitale M, et al.
NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily.
J Exp Med.
1999;189:787-796
86.
Pende D, Parolini S, Pessino A, et al.
Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells.
J Exp Med.
1999;190:1505-1516 87. Moretta A, Biassoni R, Bottino C, Moretta L. Surface receptors delivering opposite signals regulate the function of human NK cells. Semin Immunol. 2000;12:129-138[CrossRef][Medline] [Order article via Infotrieve].
88.
Wu J, Song Y, Bakker AB, et al.
An activating immunoreceptor complex formed by NKG2D and DAP10.
Science.
1999;285:730-732
89.
Chang C, Dietrich J, Harpur AG, et al.
Cutting edge: KAP10, a novel transmembrane adapter protein genetically linked to DAP12 but with unique signaling properties.
J Immunol.
1999;163:4651-4654
90.
Bauer S, Groh V, Wu J, et al.
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Science.
1999;285:727-729 91. Bahram S. MIC genes: from genetics to biology. Adv Immunol. 2000;76:1-60[Medline] [Order article via Infotrieve].
92.
Shiina T, Tamiya G, Oka A, et al.
Molecular dynamics of MHC genesis unraveled by sequence analysis of the 1,796,938-bp HLA class I region.
Proc Natl Acad Sci U S A.
1999;96:13282-13287
93.
Bahram S, Bresnahan M, Geraghty DE, Spies T.
A second lineage of mammalian major histocompatibility complex class I genes.
Proc Natl Acad Sci U S A.
1994;91:6259-6263 94. Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14:123-133[CrossRef][Medline] [Order article via Infotrieve]. 95. Li P, Willie ST, Bauer S, Morris DL, Spies T, Strong RK. Crystal structure of the MHC class I homolog MIC-A, a gammadelta T cell ligand. Immunity. 1999;10:577-584[CrossRef][Medline] [Order article via Infotrieve].
96.
Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T.
Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium.
Proc Natl Acad Sci U S A.
1996;93:12445-12450 97. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol. 2001;2:255-260[CrossRef][Medline] [Order article via Infotrieve]. 98. Pende D, Cantoni C, Rivera P, et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol. 2001;31:1076-1086[CrossRef][Medline] [Order article via Infotrieve].
99.
Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T.
Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB.
Proc Natl Acad Sci U S A.
1999;96:6879-6884
100.
Kaye J, Browne H, Stoffel M, Minson T.
The UL16 gene of human cytomegalovirus encodes a glycoprotein that is dispensable for growth in vitro.
J Virol.
1992;66:6609-6615 101. Sutherland CL, Chalupny NJ, Cosman D. The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions. Immunol Rev. 2001;181:185-192[CrossRef][Medline] [Order article via Infotrieve].
102.
Cerwenka A, Baron JL, Lanier LL.
Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo.
Proc Natl Acad Sci U S A.
2001;98:11521-11526 103. Li P, Morris DL, Willcox BE, Steinle A, Spies T, Strong RK. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol. 2001;2:443-451[Medline] [Order article via Infotrieve]. 104. Siliciano RF, Pratt JC, Schmidt RE, Ritz J, Reinherz EL. Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. Nature. 1985;317:428-430[CrossRef][Medline] [Order article via Infotrieve]. 105. Lanier LL, Ruitenberg JJ, Phillips JH. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J Immunol. 1988;141:3478-3485[Abstract]. 106. Timonen T, Patarroyo M, Gahmberg CG. CD11a-c/CD18 and GP84 (LB-2) adhesion molecules on human large granular lymphocytes and their participation in natural killing. J Immunol. 1988;141:1041-1046[Abstract].
107.
Carbone E, Ruggiero G, Terrazzano G, et al.
A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction.
J Exp Med.
1997;185:2053-2060 108. Borrego F, Robertson MJ, Ritz J, Pena J, Solana R. CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology. 1999;97:159-165[CrossRef][Medline] [Order article via Infotrieve]. 109. Tangye SG, Cherwinski H, Lanier LL, Phillips JH. 2B4-mediated activation of human natural killer cells. Mol Immunol. 2000;37:493-501[CrossRef][Medline] [Order article via Infotrieve].
110.
Valiante NM, Trinchieri G.
Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes.
J Exp Med.
1993;178:1397-1406 111. Sivori S, Parolini S, Falco M, et al. 2B4 functions as a co-receptor in human NK cell activation. Eur J Immunol. 2000;30:787-793[CrossRef][Medline] [Order article via Infotrieve]. 112. Vitale M, Falco M, Castriconi R, et al. Identification of NKp80, a novel triggering molecule expressed by human NK cells. Eur J Immunol. 2001;31:233-242[CrossRef][Medline] [Order article via Infotrieve]. 113. Roda-Navarro P, Arce I, Renedo M, Montgomery K, Kucherlapati R, Fernandez-Ruiz E. Human KLRF1, a novel member of the killer cell lectin-like receptor gene family: molecular characterization, genomic structure, physical mapping to the NK gene complex and expression analysis. Eur J Immunol. 2000;30:568-576[CrossRef][Medline] [Order article via Infotrieve]. 114. Kruit WH, Goey SH, Lamers CH, et al. High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer. J Immunother. 1997;20:312-320. 115. Kimura H, Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer. 1997;80:42-49[CrossRef][Medline] [Order article via Infotrieve]. 116. Law TM, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer. 1995;76:824-832[CrossRef][Medline] [Order article via Infotrieve]. 117. Caligiuri MA, Murray C, Soiffer RJ, et al. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J Clin Oncol. 1991;9:2110-2119[Abstract].
118.
Lim SH, Newland AC, Kelsey S, et al.
Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia 119. Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol Immunother. 1998;46:318-326[CrossRef][Medline] [Order article via Infotrieve]. 120. Cortes JE, Kantarjian HM, O'Brien S, et al. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer. 1999;85:1506-1513[CrossRef][Medline] [Order article via Infotrieve]. 121. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988;108:806-814[CrossRef][Medline] [Order article via Infotrieve].
122.
Ruggeri L, Capanni M, Casucci M, et al.
Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation.
Blood.
1999;94:333-339
123.
Colonna M, Borsellino G, Falco M, Ferrara GB, Strominger JL.
HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells.
Proc Natl Acad Sci U S A.
1993;90:12000-12004
124.
Mandelboim O, Reyburn HT, Vales-Gomez M, et al.
Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules.
J Exp Med.
1996;184:913-922
125.
Ruggeri L, Capanni M, Urbani E, et al.
Effectiveness of donor natural killer call alloreactivity in mismatched hematopoietic transplants.
Science.
2002;295:2097-3100 126. Stockerl-Goldstein KE, Blume KG. Allogeneic hematopoietic cell transplantation for adult patients with acute myeloid leukemia. In: Thomas ED,Blume KG,Forman SJ, eds. Hematopoietic Cell Transplantation. 2nd ed. Malden, MA: Blackwell Science; 1999:823-834. 127. Yu YY, Kumar V, Bennett M. Murine natural killer cells and marrow graft rejection. Annu Rev Immunol. 1992;10:189-213[CrossRef][Medline] [Order article via Infotrieve]. 128. Glass B, Uharek L, Zeis M, Loeffler H, Mueller-Ruchholtz W, Gassmann W. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. Br J Haematol. 1996;93:412-420[CrossRef][Medline] [Order article via Infotrieve]. 129. Zeis M, Uharek L, Glass B, et al. Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukaemia effect in mice. Br J Haematol. 1997;96:757-761[CrossRef][Medline] [Order article via Infotrieve]. 130. Asai O, Longo DL, Tian ZG, et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest. 1998;101:1835-1842[Medline] [Order article via Infotrieve].
131.
Koh CY, Blazar BR, George T, et al.
Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo.
Blood.
2001;97:3132-3137 132. Murphy WJ, Koh CY, Raziuddin A, Bennett M, Longo DL. Immunobiology of natural killer cells and bone marrow transplantation: merging of basic and preclinical studies. Immunol Rev. 2001;181:279-289[CrossRef][Medline] [Order article via Infotrieve].
133.
Bellone G, Valiante NM, Viale O, Ciccone E, Moretta L, Trinchieri G.
Regulation of hematopoiesis in vitro by alloreactive natural killer cell clones.
J Exp Med.
1993;177:1117-1125
134.
Meyaard L, van der Vuurst de Vries AR, de Ruiter T, Lanier LL, Phillips JH, Clevers H.
The epithelial cellular associated adhesion molecule (Ep-CAM) is a ligand for the leukocyte-associated immunoglobulin-like receptor (LAIR).
J Exp Med.
2001;194:107-112   CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
[IFN-
[TNF-
+CD56
. This
precursor is then responsive to IL-15 for maturation into a
functional CD56+ NK cell. The NK cells resulting from adult
CD34+ HPCs in stroma-free cultures following addition
of IL-15, however, resemble the CD56bright NK cell
population both functionally and phenotypically
(CD56brightCD16dim/neg),
including their NK receptor repertoire.
T cells.
and/or Fc
RI
CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition.
J Exp Med.
1990;172:1589-1598
a phase II study.
Cancer Immunol Immunother.
1992;34:337-342
